PFE Pfizer Inc. : Bullish and Bearish Analyst Opinions

PFE is struggling post-COVID, and the hit rate on recent launches is failing to offset the upcoming expirations of Eliquis and Ibrance. High R&D spending is not currently translating into enough successful launches to cover the impending revenue holes. Avoid PFE until the pipeline proves capable of replacing expiring blockbuster revenues. High R&D spending could suddenly yield a surprise blockbuster drug.

The author explicitly recommends buying PFE stock, projecting strong performance into 2026.

Cramer agreed with Bob Lang's analysis that it's time to buy big pharma names like Pfizer, Merck, and Bristol Myers for their dividends and safety in a potential slowdown. These companies have strong dividend yields (e.g., Pfizer 6.3%, Merck nearly 3%, Bristol Myers 4.3%), bullish technical indicators (money flow, cup-and-handle patterns), and are recession-resistant as medication demand is inelastic. LONG because they offer yield protection and potential capital appreciation in a potential economic slowdown, making them defensive plays. If the economy avoids a slowdown, these stocks might underperform growth sectors; drug pipeline setbacks could impact earnings.

Pfizer's experimental Lyme disease vaccine was only 73% effective in a pivotal study, a lackluster result complicated by fewer-than-expected infections. The suboptimal efficacy data and challenging study dynamics could delay regulatory approval or limit the vaccine's commercial potential in an untapped market. The stock underperformed in a strong market, down 0.7%, reflecting diminished expectations for this product. Further analysis of the data or adjustments to the trial could improve the outlook.

"It's at $26. It yields 6.4%. It's got a lot of stuff in the pipeline." Pfizer offers a high dividend yield and has a promising pipeline. Cramer's endorsement, albeit with a "whole milk" analogy (suggesting a steady, substantive hold), frames it as an income investment with potential for pipeline-driven recovery. Viewed as a value and income play for long-term investors willing to look past near-term challenges. Pipeline failures, patent cliffs on key drugs, and weak growth in its core business.

PFE trades at ~8.8x forward P/E with a 6.5% dividend yield, significantly cheaper than peers like MRK and JNJ. The market is hyper-focused on the COVID revenue drop and patent cliff, ignoring the $43B Seagen acquisition, cost cuts, and 2026 pipeline catalysts. PFE is a textbook value play with capped downside and enormous upside potential over the next 3-5 years, paying a safe dividend while you wait. The Seagen acquisition fails to deliver expected revenues, pipeline catalysts disappoint, or the patent cliff impact is worse than anticipated.

The stock's low valuation is not an opportunity but a warning of underlying fundamental problems, making it a value trap to be avoided.

"The Trump RX plan of course is developed by these private meetings with the pharma types... especially Merc and Eli Lily and J&J have been very effective at that." Companies that engage Trump privately and collectively can shape policy in their favor without triggering his public attacks. The pharmaceutical sector successfully used this playbook to navigate drug pricing policies, resulting in a plan that was much better for the industry than critics anticipated. LONG. These large pharma companies have proven they can manage political and regulatory risk under Trump by using private, collective influence to protect their margins. The presence of RFK Jr. in the administration is noted as a "pernicious problem" that could introduce unpredictable regulatory or narrative risks for the sector.

Pfizer: Obesity Hype And Vaccine Policy Shocks $PFE $PFE:CA $ZPFE:CA #stocks #business #stockmarket https://t.co/ImyPSFERxy

"I would be surprised to see tariffs put back on the table with respect to the drugmakers, because a lot of the deals... specifically excluded tariffs being imposed on those companies." The market may be pricing in "Trump Trade" tariff risks across the board, but Big Pharma (like Pfizer, where Gottlieb is a board member) has regulatory immunity due to prior pricing agreements. This makes them a defensive play against trade war volatility. LONG. The administration reneges on verbal/written agreements regarding tariff exclusions.

The author suggests that Pfizer's high dividend yield is not secure, making it an unattractive or risky investment for those seeking stable income.

Solodin uses Pfizer as an example of a "dead money" stock—trading between $22 and $29 with a high dividend yield (7%). Investors holding for the dividend face price risk. By selling Covered Calls (e.g., Strike 35) when volatility spikes (like during earnings), the investor collects extra yield (~5%) on top of dividends. NEUTRAL/INCOME. If the stock falls, the call premium buffers the loss. If it rises, the investor is happy to exit at the strike price. The stock rallies aggressively past the strike, forcing the investor to sell their shares and lose the dividend stream.

Schiller advises that for Democrats to win, they must "zero in on core issues, health care affordability and individual security." If Democrats successfully consolidate their messaging around "health care affordability" heading into the midterms, this typically signals legislative pressure on drug pricing and insurance premiums. Watch for increased volatility or downside pressure in the Healthcare sector as political rhetoric heats up regarding price controls. Democrats fail to unify their message (as Schiller notes they often "find a way to lose"), leaving the sector untouched.

Activist activity is surging. Elliott has a >10% stake in Norwegian Cruise Line (NCLH). Starboard is pushing TripAdvisor (TRIP) for a sale. Jana Partners is in Pfizer (PFE). Danaher (DHR) is acquiring Masimo (MASI). Activists (Elliott, Starboard) are aggressively pushing for immediate value unlocking via sales, splits, or operational overhauls. This historically creates a floor for the stock price and drives short-term upside as the market prices in M&A premiums. Long the activist targets (NCLH, TRIP, MASI). Deal talks fail; activists exit without forcing change.